Donna L Forrest
Overview
Explore the profile of Donna L Forrest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu A, Yen R, Grasedieck S, Lin H, Nakamoto H, Forrest D, et al.
Leukemia
. 2023 Oct;
37(12):2426-2435.
PMID: 37848633
Imatinib Mesylate (imatinib) was once hailed as the magic bullet for chronic myeloid leukemia (CML) and remains a front-line therapy for CML to this day alongside other tyrosine kinase inhibitors...
2.
Yen R, Grasedieck S, Wu A, Lin H, Su J, Rothe K, et al.
Leukemia
. 2022 Aug;
36(10):2443-2452.
PMID: 35999259
Despite the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia (CML), they are not usually curative as some patients develop drug-resistance or are at risk of disease relapse...
3.
Stubbins R, Stamenkovic M, Roy C, Rodrigo J, Chung S, Kuchenbauer F, et al.
Eur J Haematol
. 2022 Feb;
108(5):437-445.
PMID: 35122325
Objectives: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio-economic factors. We determined AML incidence in older adults and the impact of socio-economic factors...
4.
Rothe K, Babaian A, Nakamichi N, Chen M, Chafe S, Watanabe A, et al.
Cell Stem Cell
. 2020 May;
27(1):110-124.e9.
PMID: 32413332
Patients with chronic myeloid leukemia (CML) often require lifelong therapy with ABL1 tyrosine kinase inhibitors (TKIs) due to a persisting TKI-resistant population of leukemic stem cells (LSCs). From transcriptome profiling,...
5.
Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R, et al.
Blood
. 2020 Apr;
136(5):596-609.
PMID: 32270193
Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. To investigate the role of microRNAs (miRNAs) in regulating drug resistance and leukemic stem cell (LSC)...
6.
Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, et al.
Sci Transl Med
. 2019 Jul;
11(501).
PMID: 31316004
LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.
7.
Savoie M, Bence-Bruckler I, Huebsch L, Lalancette M, Hillis C, Walker I, et al.
Leuk Res
. 2018 Sep;
73:67-75.
PMID: 30227318
The majority of patients with TKI failure respond to HCT. However, the relapse risk remains high. This study has evaluated transplant outcomes in 223 CML patients with TKI failure due...
8.
Limvorapitak W, Barnett M, Hogge D, Forrest D, Nevill T, Narayanan S, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Aug;
18(11):e481-e491.
PMID: 30100330
Introduction: Optimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia remains an area of ongoing research. We aimed to retrospectively compare outcomes following autologous stem cell transplantation (autoSCT) with...
9.
Zhu K, Song K, Connors J, Leitch H, Barnett M, Ramadan K, et al.
Br J Haematol
. 2018 May;
181(6):782-790.
PMID: 29741758
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined...
10.
Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, et al.
Sci Transl Med
. 2018 Feb;
10(427).
PMID: 29437150
Overcoming drug resistance and targeting leukemic stem cells (LSCs) remain major challenges in curing BCR-ABL human leukemia. Using an advanced drug/proliferation screen, we have uncovered a prosurvival role for protein...